Despite intense research, there is no way to stop or delay the progression of HD and current treatments merely treat symptoms (1, 4) . However, a number of promising studies have aimed at improving cell survival of affected areas (reviewed in (6) ).
Unlike other neurological disorders, such as Alzheimer's and Parkinson's diseases, HD is monogenic (5) . Therefore, therapeutic strategies need only target the expression of the causal gene, to reverse and treat the effects of the mutant protein. However, since wt HTT protein is widely expressed (7) , is essential for early embryonic development (8) and is required for neuronal function and survival in the brain (9) , it is important to specifically reduce the expression of the mutant protein, while leaving the expression of the wt protein as unaffected as possible.
Several approaches using synthetic nucleic acids that selectively target the mutant allele are currently being developed (reviewed in (10) ). Recently, RNA interference (RNAi) was shown to reduce expression of mutant HTT (11) (12) (13) . Although this technique could be very powerful, mutant-selective RNAi depends on targeting single nucleotide or deletion polymorphisms that differentiate between alleles, and these often differ from patient to patient. However, there is evidence that partial repression of wt HTT can be tolerated (14, 15) , suggesting that generic approaches that repress both alleles should also be pursued. Peptide and locked nucleic acids (PNAs and LNAs) are generic and yet some promising partially-selective inhibition of expanded CAG repeats of the ataxin-3 and HTT genes has been reported (16, 17) . Recently, there has even been sustained disease reversal using antisense oligonucleotides (18) . Also aiming to reduce the levels of mutant protein, a different approach was proposed by Bauer et al. who designed a polyglutamine-binding peptide, fused to heat shock cognate protein 70 binding motif, to direct degradation of mutant HTT via chaperonemediated autophagy (19) . Intrastriatal recombinant adeno-associated virus (rAAV) delivery of this fusion protein showed a strong therapeutic effect.
In this study, we examined the use of zinc finger proteins (ZFP) as a complementary approach to reduce the expression of mutant HTT, which could be used in tandem with any of the above approaches. Because zinc fingers can be readily re-engineered to bind different DNA sequences (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) , including CAG-repeats (30) , they could in principle be used to target the HTT gene at a transcriptional level. Furthermore, zinc fingers can be easily concatenated into long chains, and different linker designs can alter the interaction kinetics substantially (31) . This suggested to us that a systematic appraisal of different-length ZFP, with appropriate linker designs, might reveal an optimal configuration for repressing mutant HTT, while leaving the wt allele relatively unaffected.
We therefore designed a ZFP able to recognize and bind poly-5'-GC (A/T)-3', such that it would recognize both poly-CAG and its complementary DNA strand. The resulting ZFP chains (from 4-to 18-fingers) were able to repress target genes with longer CAG repeats preferentially, when compared to shorter repeats. This was carried out both in transient transfection reporter assays and with stable expression for 20 days, against full HTT chromosomal targets, in various model cell lines for HD.
Ultimately, we tested the most effective ZFP in vivo in the R6/2 HD mouse model, using AAV for delivery, establishing a proof-of-principle for gene repression by synthetic zinc fingers in the brain.
Results
Designing long ZFP chains to bind expanded CAG repeats. Zinc fingers can be concatenated to make long multi-finger chains (31, 32) and, to date, no one has systematically explored the binding modes of different-length ZFP to long repetitive DNA tracts. We therefore used rational design to construct a zinc finger (ZFxHunt) that would bind 5'-GC (A/T)-3', such that poly-finger proteins would bind poly-GCA and poly-GCT (see Methods; Fig. 1 ). Both DNA strands were targeted to increase the avidity for low-copy chromosomal targets. For structural reasons, zinc finger chains with canonical linkers lose their register with cognate DNA after 3 fingers. Therefore, extra -Gly (31) or 29-residue linkers were added after every 2-and 6-fingers, respectively (full sequences given in SI). In this way, different numbers of fingers could be tested for length-dependent discrimination.
First, zinc finger chains containing either 4, 6 or 12 ZFxHunt domains were constructed and tested in gel shift assays, for binding to double-stranded CAG probes; longer ZFPs gave more complete binding (Fig. 1B) . Intriguingly, distinct bound complexes were observed, indicating that the ZFPs found single thermodynamic equilibria and were not trapped by kinetic intermediates. Highly-repetitive zinc fingers and DNA might have been expected to form contiguous partial binding events, which would have resulted in broad smears in gel shifts; this is not the case.
Nonetheless, the 12-finger ZFP did give a lower, secondary shift, presumably caused by a 6-finger degradation by-product (zinc fingers can be unstable in linker regions (33) ). To our knowledge, these 12-finger (and subsequently 18-finger) domains are the longest functional artificial ZFP chains ever built.
To test whether ZFxHunt proteins are able to bind both strands of a CAG DNA probe, ZF6xHunt was assayed by gel shift, and was shown to bind equally to both a CAG repetitive probe, (GCA) x6 , and to an alternate CAG-CTG probe, (GCA-GCT) x3 (Fig.   1C ). Furthermore, when compared to mutated sequences, ZF6xHunt showed specificity for (CAG) x7 (Fig. 1D ). In summary, we built multi-finger ZFP able to bind poly 5'-GC (A/T)-3' DNA probes specifically and efficiently in vitro.
Repression of polyQ reporter genes. Our starting hypothesis was that zinc finger proteins could preferentially bind longer CAG repeats through a mass action mechanism. Longer CAG repeats contain more target sites, and so should be bound and repressed more at any given ZFP concentration. Similarly, longer ZFP chains should also have a higher affinity, allowing one to balance expression, repression and length-preference. Although plasmid-based assays ultimately have different mass action kinetics to single-copy target chromosomal assays, they allowed us to verify our hypothesis rapidly before moving onto chromosomal targets.
ZFxHunt of different lengths were therefore tested using reporter vectors with Nterminal CAG repeats from the human HTT gene in frame with EGFP (Q0, Q10, Q35 and Q104; Q=CAG). To assess non-specific effects, an HcRed reporter was cloned in a different region of the same vector, under an independent promoter ( Fig. 2A ).
HEK293T cells were transiently co-transfected with the indicated reporter and ZFxHunt vectors, driven by CMV promoters. As gene therapy delivery vectors (used later) have a limited packaging capacity, which is exceeded by 12-fingers, we also tested an 11-finger construct. We found a similar expression levels and activity between ZF12xHunt and ZF11xHunt (Fig. S1) , and so used ZF11xHunt in all subsequent assays.
Three assays were used to measure ZFxHunt repression: quantifying EGFP and HcRed fluorescent cells using Fluorescence-Activated Cell Sorting (FACS), EGFP protein levels in Western blots, and EGFP and HcRed mRNA levels in qRT-PCR (Fig. 2B-D) . In these experiments, ZFxHunt with 6-, 11-and 18-fingers all repressed the two longer CAG-repeats strongly (5-9-fold: 80-90% repression) whereas ZF4xHunt was slightly weaker (2-4-fold: 50-75% repression). A Student's t-test analysis revealed that ZF11xHunt gave significant repression of longer polyQ reporter genes the most consistently out of all ZF constructs, with no significant unspecific repression of the HcRed controls (p-values in Supplementary Tables S1,2). Verifying that the results were not specific to ZFP under the CMV promoter, similar results were obtained with the phosphoglycerate kinase (PGK) promoter (Fig. S2 ). Although binding interactions (and thus particular length-preference) can always be modulated by changing the effective concentration of each species, the main conclusion that can be drawn here is that there is a positive relationship between CAG repeat number and repression level. Furthermore, ZF6-, ZF11-and ZF18xHunt are all strong repressors of longer repeats under these conditions.
Competition assays show preferential repression of long CAG-repeats by
ZFxHunt. Up to this point, the zinc fingers had displayed length preference for single CAG-repeat targets in cells. Another test of potential length-preference is for discrimination against two targets per cell, each with a different number of CAGrepeats. HEK293T cells were therefore co-transfected with three plasmids: the indicated polyQ-EGFP and polyQ-mCherry reporter vectors, together with various ZFxHunt vectors (Fig. 3) . The relative expression of the two reporters was measured by FACS (EGFP or mCherry positive cells). Figure 3 shows that the longer CAGrepeats are preferentially repressed by all ZFxHunt, so that cells are dominated by the shorter green or red constructs when their opposite counterpart is longer; this is seen directly by looking at the ratio of green-to-red expression. This can be explained most simply by mass action (longer CAG-repeats contain more target sites, so are bound and repressed more).
This assay demonstrates the potential of ZFxHunt for CAG-length discrimination.
Therefore length preference exists, even for multiple different-length CAG-repeats within the same cell. The remaining caveat is that the system still needs to be tailored (expression levels, zinc finger length, repression strength) for the particular cellular environment. We therefore moved next to testing in a more physiological chromosomal cellular environment.
Chromosomal repression of mutant HTT in a HD model cell line. Since ZF4xHunt had weaker binding and length preference (Fig. 2, 3) , and since ZF12-and ZF18xHunt are beyond the packaging limit of AAV, we focussed on testing ZF6xHunt and ZF11xHunt, on chromosomal HTT genes. STHdh cells (34) capsid, efficiently transduces neurons (and most glial and some ependymal cells) and appears to be the most efficient pseudotype for transducing large volumes of the striatum (37) . R6/2 mice are one of the most-widely used models of HD because they show highly reproducible early onset symptoms, allowing the use of fewer animals (38) . Although R6/2 have very long CAG-repeats (range 115-160), which are rarely found in patients (typically in the 42-45 range), they are nonetheless ideal to assay acute phenotypic reversal at the molecular, histologic and early-symptom levels (39).
Therefore, R6/2 mice were stereotaxically injected at 4 weeks of age with AAV2/1 expressing ZF11xHunt-Kox-1.
We initially tested vectors expressing the ZF under a CMV promoter, but we observed very low levels of expression of the ZF protein and mRNA, and no repression of mutant HTT. CMV promoters can be quickly silenced by DNA methylation (40) , whereas high and persistent levels of expression can be achieved in the central nervous system with rAAV using the CAG promoter (CMV enhancer, chicken beta-actin hybrid promoter) and a WPRE (Woodchuck hepatitis virus postranscriptional regulatory element) (41, 42) . We therefore produced a second generation of rAAV using these elements.
CAG-WPRE constructs were injected into the striatum of one brain hemisphere, with AAV2/1-GFP control injections (equal titre) into the other. ZFP striatal expression was confirmed by Western blot (Fig. S5A ), while GFP fluorescence shows transduction of large striatal volumes ( Neither striatal volume nor cell density in the striatum was affected by treatment or genotype, indicating that the reduction of mutant HTT was not due to a loss of cells and providing no evidence of ZFxHunt toxicity at this level (ANOVA, Genotype p>0.1; Treatment p>0.1) (Table S4) To assess motor coordination, male R6/2 mice and their wt littermates were tested at 3
weeks of age for their baseline performance (latency to fall) in the accelerating rotarod test. They subsequently received bilateral striatal injections at 4 weeks, as described above. Repeated measures ANOVA comparing the decline in R6/2 performance revealed that GFP-treated R6/2 were significantly impaired as compared to their GFP-treated wt controls (p=0.035), whereas the AAV2/1-ZF11xHunt-Kox-1 treated R6/2 mice not different from the wt mice (p>0.1) (Fig. 7C ).
In our experiments, R6/2 mice do not experience any weight-loss or changes in survival compared to their wt counterparts and thus these phenotypes cannot be used as endpoints. We did not observe any significant difference in weight between wt and R6/2, treated and untreated mice ( Fig. S9 ) and no mice died during the experiment, either with or without treatment, so no conclusion can be drawn about the effect of treatment on these phenotypes.
The data presented establish a proof-of-principle that zinc finger repressors can be active after striatal delivery, with HTT reduction at the RNA and protein level, and significant improvements in disease phenotypes in a HD mouse model.
Discussion
In this study, we have described the design of a ZFP able to recognize and bind both DNA strands of a stretch of CAG repeats, by recognizing both poly-GCA and -GCT triplets, to induce transcription repression. As shown in Figure One major in vitro observation was that longer CAG-repeats were repressed more by particular finger constructs under given conditions, suggesting that mass action can be exploited to give a degree of length preference. Binding to different lengths of CAGrepeats is, of course, altered by the effective concentrations of both zinc finger and target. We therefore had to find empirically which length of zinc finger and which expression construct would give an effective dose to discriminate between the lengths of CAG-repeats in a chosen HD mouse model.
By first using a model cell line derived from striatial cells of a knock-in HD mouse model (the full HTT gene, with variable CAG-repeats in exon 1) (34), we found effective constructs and doses which gave a great deal of specificity for repressing mutant Huntingtin at a chromosomal level. Although repression of the shorter wt HTT protein is well tolerated for several months in animal models (14, 45) , it is desirable to preferentially target the mutant allele (13, 16) , and one should not affect other CAGrepeat containing genes. In fact, under the dosages tested, we found conditions in which mutant HTT was strongly repressed for a sustained period of 20 days, with no apparent side-effects on other shorter CAG-repeat genes. Therefore the next step was to explore whether repression could also be achieved in the brain, using gene therapy vectors for delivery.
Gene therapy is an attractive therapeutic strategy for various neurodegenerative diseases. For example, lentiviral vectors have been used to mediate the widespread and long-term expression of transgenes in non dividing cells such as mature neurons (46) . A rAAV vector was also used by Rodriguez-Lebron et al. (47) to deliver antimutant HTT shRNAs in HD model mice, thereby reducing striatal mutant HTT levels and slowing progression of the HD-like phenotype. As outlined in the introduction, several strategies to target HTT have shown promise (11-13, 16, 17, 19) . However, repression in the brain by a synthetic transcription factor has never been reported. It was unknown whether sufficient levels of protein could be produced after in vivo delivery to see any repression, whether transcription repression would be sufficient to reduce protein levels, and whether such constructs would show acute toxicity. In fact,
we were able to get effective repressors that were well-tolerated, but this required a degree of further optimisation, including the use of a strong CAG promoter and WPRE (42) . With these improvements we observed selective repression of mutant HTT RNA, a reduction in HTT protein aggregates and an alleviation of associated HD phenotypic deficits.
Overall, the results presented in this study establish a proof-of-principle that ZFs can acutely repress mutant HTT in vivo via striatal injection, in a dose-dependent manner.
These results imply that it is worth pursuing these constructs to test a multitude of possible gene therapy vector and zinc finger variants, with a view to optimising potential therapeutic benefit.
Materials and Methods
Vectors. To build a ZFP that recognizes both GCA and GCT DNA sequences, we based our designs on two previous studies. Choo et al. (44) and 18 by subcloning (full sequences given in Supplementary Information).
ZF6xHunt was subcloned into the mammalian expression vector pTarget (Promega).
A 3xFLAG tag sequence (DYKDHDG DYKDHDI DYKDDDDK) was introduced by PCR at the N-terminus, and either FokI endonuclease domain or Kox-1 (KRAB repression domain) coding sequences were introduced at the C-terminus, with a 3xGGGGS linker.
The pEH vector series was cloned in two steps. First, EGFP coding region was excised from pEGFP-N1 (Clontech), using HindIII/XbaI, and cloned into pGL4.13
(Promega) to give pSV40-EGFP. Then, a PCR product containing CMV-HcRedpolyA and ClaI linkers was cloned into pSV40-EGFP (partially digested with ClaI).
The EGFP start codon was mutated to Alanine by site directed mutagenesis, and PCR fragments containing human HTT exon I from different human genomic templates (to obtain different number of CAG repeats) were cloned into the pEH EcoRI site, upstream and in frame with EGFP (pEH-Q series). The pSV40-mCherry vector series were generated by replacing EGFP from the pSV40-EGFP vector series by mCherry using XmaI/XbaI sites. Table S3 . Accelerating rotarod. Mice (R6/2 mice: ZFP-treated n=12; GFP-mock treated, n=12;
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WT mice: ZFP-treated n=14; GFP-mock treated, n=14) were trained at week 3 of age to stay on the rod at a constant speed of 4 r.p.m. until they reached a criterion of 3 consecutive minutes on it. In the testing phase, mice were put in the rotarod at 4 r.pm. and the speed was constantly increased for 2 minutes to 40 r.p.m. The assay was repeated twice and the maximum latency to fall from the rod was recorded. Decline in performance was calculated as the difference in the latency to fall from pre-surgery levels with respect to weeks 5 and 7.
Statistical analysis. Error bars in figures are one standard error based on at least three biological replicates. Data of the repression of polyQ reporter genes experiments were analysed using a Student's t test against an expected value of 1 (no repression or activation). Expected percentages of mice clasping were inferred of our population of un-operated R6/2 mice, and a Chi-square test for goodness-of-fit was applied to the observed percentages in operated groups. Data of the accelerating rotarod test were analyzed using repeated measures ANOVA with week as within-subject factor and group as between-subject factor, followed by a post-hoc analysis using the Bonferroni correction.
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